{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:47:41Z","timestamp":1791848861745,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012416","name":"Bundesministerium f\u00fcr Digitalisierung und Wirtschaftsstandort","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010132","name":"\u00d6sterreichische Nationalstiftung f\u00fcr Forschung, Technologie und Entwicklung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.dld.2022.12.014","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T07:29:27Z","timestamp":1673681367000},"page":"431-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["The Baveno VII concept of cirrhosis recompensation"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3403-3372","authenticated-orcid":false,"given":"Benedikt Silvester","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2022.12.014_bib0001","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0002","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0003","first-page":"0","article-title":"Baveno VII - renewing consensus in portal hypertension","author":"de Franchis","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0005","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1776","article-title":"Associations between alcohol use and liver-related outcomes in a large national cohort of patients with cirrhosis","volume":"5","author":"Pearson","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2022.12.014_bib0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","article-title":"Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study","volume":"111","author":"Vorobioff","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.014_bib0008","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/tri.13008","article-title":"Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case\u2013control study","volume":"30","author":"Aravinthan","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.dld.2022.12.014_bib0009","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.02.033","article-title":"A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement","volume":"75","author":"Pose","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0010","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/lt.25485","article-title":"Superior wait-list outcomes in patients with alcohol-associated liver disease compared with other indications for liver transplantation","volume":"25","author":"Giard","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2022.12.014_bib0011","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3748\/wjg.v24.i26.2785","article-title":"Liver transplantation and alcoholic liver disease: history, controversies, and considerations","volume":"24","author":"Marroni","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.014_bib0012","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series\u2606","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0013","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.12.014_bib0014","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dld.2022.12.014_bib0016","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.014_bib0017","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0018","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0019","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.014_bib0021","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/jmv.25552","article-title":"Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort","volume":"91","author":"Macken","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.dld.2022.12.014_bib0022","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity\u2014LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2022.12.014_bib0023","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0024","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0025","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/liv.13878","article-title":"Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting","volume":"38","author":"Perricone","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2022.12.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.09.033","article-title":"In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent","volume":"19","author":"Bittermann","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0027","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/liv.13588","article-title":"The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: a national real-life experience","volume":"38","author":"Martini","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2022.12.014_bib0028","first-page":"45","article-title":"Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: a long-term single-center experience","author":"Nabatchikova","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.014_bib0029","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0030","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2014.145","article-title":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis","volume":"109","author":"Kim","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.014_bib0031","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0032","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0033","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.27723","article-title":"Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis","volume":"61","author":"Jang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.014_bib0034","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.014_bib0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort","volume":"34","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.014_bib0036","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-0012.2005.00340.x","article-title":"Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive\/HBeAg-negative chronic hepatitis B","volume":"19","author":"Nikolaidis","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.dld.2022.12.014_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043083","article-title":"Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study","volume":"11","author":"Xu","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.dld.2022.12.014_bib0038","first-page":"0","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0039","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.08.009","article-title":"New terms for fatty liver disease other than MAFLD: time for a reality check","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0041","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2022.12.014_bib0042","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/lt.24383","article-title":"Model for end-stage liver disease limbo, model for end-stage liver disease purgatory, and the dilemma of treating hepatitis C in patients awaiting liver transplantation","volume":"22","author":"Carrion","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2022.12.014_bib0043","article-title":"Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2022.12.014_bib0044","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.dld.2022.12.014_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0046","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.014_bib0047","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","article-title":"Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality","volume":"74","author":"Costa","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0048","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0049","first-page":"379","article-title":"Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation","volume":"70","author":"Monteiro","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.014_bib0050","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fern\u00e1ndez","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0051","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"Reiberger","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0052","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study","volume":"35","author":"Pinter","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2022.12.014_bib0053","first-page":"146","article-title":"Vascular endothelial growth factor promotes fibrosis resolution and repair in mice","author":"Yang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.014_bib0054","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/lt.25781","article-title":"Serum microRNA signatures in recovery from acute and chronic liver injury and selection for liver transplantation","volume":"26","author":"Salehi","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.dld.2022.12.014_bib0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2022.12.014_bib0056","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-2008-1059304","article-title":"Influence of alcohol on portal-vein haemodynamics in nutritional-toxic cirrhosis of the liver","volume":"118","author":"Klein","year":"1993","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.dld.2022.12.014_bib0057","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2022.12.014_bib0058","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0059","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jhep.2009.05.031","article-title":"Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension","volume":"51","author":"Manolakopoulos","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0060","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0061","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/gutjnl-2020-322712","article-title":"Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes","volume":"70","author":"Jachs","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2022.12.014_bib0062","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","article-title":"Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis","volume":"58","author":"Reiberger","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0063","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.14309\/ajg.0000000000001399","article-title":"Impact of alcohol abstinence on the risk of hepatocellular carcinoma in patients with alcohol-related liver cirrhosis","volume":"116","author":"Rodr\u00edguez","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2022.12.014_bib0064","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","article-title":"Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR","volume":"76","author":"D'Ambrosio","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2010.02.026","article-title":"Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease","volume":"53","author":"Eun","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2022.12.014_bib0066","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/gut.2010.221846","volume":"60","author":"Papatheodoridis","year":"2011","journal-title":"Gut"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582200860X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086582200860X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:21:23Z","timestamp":1761625283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086582200860X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S159086582200860X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.12.014","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Baveno VII concept of cirrhosis recompensation","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}